DROPERIDOL | A208197 | HIKMA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Regulatory Affairs Consulting FDA-2025-P-0253 · 5 docket documents Robert van Osdel, a regulatory affairs consultant, filed this citizen petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA determine whether the reference listed drug Inapsine Injection 2.5 mg/mL (droperidol, N016796) was withdrawn from marketing for | 505(q) | 2025-01-17 | Granted | Regulatory Affairs Consulting |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.